Newsfeeds - Spark Newswire

2 minute read

Replimune To Present At ASCO Jun. 5-6

Today, 4:42 PM

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today

REPL

2 minute read

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst

By Joel Elconin

Today, 4:42 PM

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than its all-time high price ($174.79 vs. $66.50).

DAWN

1 minute read

SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $48

By Benzinga Newsdesk

Today, 4:42 PM

SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $49 to $48.

REPL

1 minute read

Earnings

Replimune Group: Q4 Earnings Insights

By Benzinga Insights

Today, 4:42 PM

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed estimated earnings by 3.45%, reporting an EPS of $-0.6 versus an estimate of $-0.58.

REPL

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 4:42 PM

On Friday, 1043 companies hit new 52-week lows.

AAOI

1 minute read

JP Morgan Maintains Overweight on Replimune Group, Lowers Price Target to $39

By Benzinga Newsdesk

Today, 4:42 PM

JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and lowers the price target from $47 to $39.

REPL

4 minute read

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More

By Shanthi Rexaline

Today, 4:42 PM

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

ADMP